Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.58 |
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | ARG2 | P78540 | 4/20 | 0.47 |
| ▸ | ARG1 | P05089 | 3/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.46 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | GGT1 | P19440 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550454 | 0.88 | OTC (0.54) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL30411132 | 0.88 | OTC (0.54) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL31207026 | 0.86 | OTC (0.53) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL29128940 | 0.86 | OTC (0.53) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL17451658 | 0.85 | GSR (0.52) | OTCGSRDPP7 | |
| SCHEMBL6672850 | 0.85 | OTC (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL14682811 | 0.85 | OTC (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL5974000 | 0.85 | OTC (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL5973446 | 0.85 | OTC (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL6183879 | 0.85 | OTC (0.58) | OTCGSRARG2ARG1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160375146-A1 | Biologically Active Insulin Derivatives | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375146-A1 | Biologically Active Insulin Derivatives | IAPP, INSR, IGFBP1 | OTC 1684/4885GSR 1192/4885ARG2 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.